2344-17-4 Usage
General Description
NSC56143, also known as 3,6-bis(4-hydroxy-3-methoxyphenyl)-1,2,4,5-tetrazine, is a compound that has been studied for its potential anticancer properties. Research has shown that NSC56143 induces apoptosis, or programmed cell death, in cancer cells by disrupting the functions of mitochondria and causing oxidative stress. NSC56143 has also been found to inhibit the growth and proliferation of cancer cells by interfering with the cell cycle and promoting DNA damage. Additionally, NSC56143 has been investigated for its ability to inhibit the growth of cancer stem cells, which are a subpopulation of cells within tumors that are thought to contribute to tumor progression and resistance to therapy. Overall, NSC56143 shows promise as a potential therapeutic agent for the treatment of cancer, and further research is needed to fully understand its mechanisms of action and potential clinical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 2344-17-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,3,4 and 4 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 2344-17:
(6*2)+(5*3)+(4*4)+(3*4)+(2*1)+(1*7)=64
64 % 10 = 4
So 2344-17-4 is a valid CAS Registry Number.
InChI:InChI=1/C5H2Cl2F3N3/c6-2-1(11)3(7)13-4(12-2)5(8,9)10/h11H2
2344-17-4Relevant articles and documents
Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes
Deninno, Michael P.,Wright, Stephen W.,Etienne, John B.,Olson, Thanh V.,Rocke, Benjamin N.,Corbett, Jeffrey W.,Kung, Daniel W.,Dirico, Kenneth J.,Andrews, Kim M.,Millham, Michele L.,Parker, Janice C.,Esler, William,Van Volkenburg, Maria,Boyer, David D.,Houseknecht, Karen L.,Doran, Shawn D.
, p. 5721 - 5726 (2012/09/22)
PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development.
